LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial
Crossref DOI link: https://doi.org/10.1186/s12933-016-0341-5
Published Online: 2016-02-10
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
,
Masmiquel, L.
Leiter, L. A.
Vidal, J.
Bain, S.
Petrie, J.
Franek, E.
Raz, I.
Comlekci, A.
Jacob, S.
van Gaal, L.
Baeres, F. M. M.
Marso, S. P.
Eriksson, M.
Funding for this research was provided by:
Novo Nordisk
